Brief: Annovis Bio's Buntanetap Found Safe And Effective In High-Risk Alzheimer's Patients
11/06/2024 13:14
June 11 (Reuters) - Annovis Bio Inc ANVS.N :
* ANNOVIS BIO’S BUNTANETAP FOUND SAFE AND EFFECTIVE IN
HIGH-RISK
ALZHEIMER'S PATIENTS
* ANNOVIS BIO INC: ANNOVIS BIO IS PLANNING AN 18-MONTH PHASE
III
TRIAL FOCUSING ON BIOMARKER-POSITIVE EARLY AD PATIENTS
Source text for Eikon: ID:nGNX460wGk
Further company coverage: ANVS.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Annovis Bio
See all newsAnnovis Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Annovis Bio Q2 loss widens as R&D costs rise
Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman